ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

ADVM Adverum Biotechnologies Inc

14.14
-0.52 (-3.55%)
Mar 28 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 109,879
Bid Price 12.89
Ask Price 15.49
News -
Day High 14.815

Low
6.81

52 Week Range

High
29.80

Day Low 13.83
Share Name Share Symbol Market Stock Type
Adverum Biotechnologies Inc ADVM NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
-0.52 -3.55% 14.14 19:00:00
Open Price Low Price High Price Close Price Previous Close
14.63 13.83 14.815 14.14 14.66
Trades Shares Traded VWAP Financial Volume Average Volume 52 Week Range
2,791 109,879 US$ 14.34 US$ 1,575,864 - 6.81 - 29.80
Last Trade Type Quantity Price Currency
17:09:04 1 US$ 13.86 USD

Adverum Biotechnologies Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
1.42B 101.03M - 0 -154.54M -1.53 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Adverum Biotechnologies News

Date Time Source News Article
3/18/202415:05GlobeNewswire Inc.Adverum Biotechnologies Reports Fourth Quarter and Full Year..
3/04/202415:40Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of..
2/28/202415:05GlobeNewswire Inc.Adverum Biotechnologies to Participate in the TD Cowen 44th..
2/22/202414:47Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial..
2/21/202414:39Edgar (US Regulatory)Form D - Notice of Exempt Offering of Securities
2/15/202415:17Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial..
2/14/202419:26Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial..
2/14/202415:33Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
2/14/202415:30Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial..
2/14/202415:27Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
2/14/202415:05Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial..
2/12/202407:00GlobeNewswire Inc.Adverum Biotechnologies to Participate in the Oppenheimer..
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No ADVM Message Board. Create One! See More Posts on ADVM Message Board See More Message Board Posts

Historical ADVM Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week15.6917.6513.6714.95408,010-1.55-9.88%
1 Month19.8020.9013.6717.501,638,449-5.66-28.59%
3 Months8.58929.808.0018.442,304,7135.5564.63%
6 Months16.7029.807.4017.341,214,327-2.56-15.33%
1 Year7.84829.806.8116.80804,6726.2980.17%
3 Years99.20108.505.3122.751,222,203-85.06-85.75%
5 Years52.10269.805.3161.501,210,581-37.96-72.86%

Adverum Biotechnologies Description

Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single in-office intravitreal IVT injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust sustained treatment response reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor VEGF injections.

Your Recent History

Delayed Upgrade Clock